NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, based on its patented NanoStat™ technology platform.

Founded in 2000 as a spin-out from the Center for Biologic Nanotechnology at the University of Michigan, NanoBio’s lead product candidates target treatments for herpes labialis (cold sores), onychomycosis (nail fungus), vaginitis, cystic fibrosis and intranasal & intramuscular vaccines for influenza, RSV, HSV2 and anthrax.